Cystatin SN is a Potent Upstream Initiator of Epithelial Derived Type 2 Inflammation in Chronic Rhinosinusitis.

Angela L. Nocera,Sarina K. Mueller,Alan D. Workman,Dawei Wu,Kristen McDonnell,Peter M. Sadow,Mansoor M. Amiji,Benjamin S. Bleier
DOI: https://doi.org/10.1016/j.jaci.2022.04.034
IF: 14.29
2022-01-01
Journal of Allergy and Clinical Immunology
Abstract:Background: Cystatin SN (CST1) and cystatin SA (CST2) are cysteine protease inhibitors that protect against allergen, viral, and bacterial proteases. Cystatins are overexpressed in the setting of allergic rhinitis and chronic rhinosinusitis with nasal polyps (CRSwNP); however, their role in promoting type 2 inflammation remains poorly characterized. Objective: The purpose of this study was to use integrated polyomics and a murine exposure model to explore the link between cystatin overexpression in CRSwNP and type 2 inflammation. Methods: In this institutional review board- and institutional animal care and use committee-approved study, we compared tissue, exosome, and mucus CST1 and CST2 between CRSwNP and controls (n = 10 per group) by using matched whole exome sequencing, transcriptomic, proteomic, posttranslational modification, histologic, functional, and bioinformatic analyses. C57/BL6 mice were dosed with 3.9 mg/mL of CST1 or PBS intranasally for 5 to 18 days in the presence or absence of epithelial ABCB1a knockdown. Inflammatory cytokines were quantified by using Quansys multiplex assays or ELISAs. Results: Of the 1305 proteins quantified, CST1 and CST2 were among the most overexpressed protease inhibitors in tissue, exosome, and mucus samples; they were localized to the epithelial layer. Multiple posttranslational modifications were identified in the polyp tissue. Exosomal CST1 and CST2 were strongly and significantly correlated with eosinophils and LundMackay scores. Murine type 2 cytokine secretion and T(H)2 cell infiltration increased in a time-dependent manner following CST1 exposure and was abrogated by epithelial knockdown of ABCB1a, a regulator of epithelial cytokine secretion. Conclusion: CST1 is a potent upstream initiator of epithelialderived type 2 inflammation in CRSwNP. Therapeutic strategies targeting CST activity and its associated posttranslational modifications deserve further interrogation.
What problem does this paper attempt to address?